Related references
Note: Only part of the references are listed.Clinical efficacy of WT1 peptide vaccination in patients with acute myelogenous leukemia and myelodysplastic syndrome
Masaki Yasukawa et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS
Ulrich Keilholz et al.
BLOOD (2009)
Cancer Immunotherapy: The Role Regulatory T Cells Play and What Can be Done to Overcome their Inhibitory Effects
Ulf Petrausch et al.
CURRENT MOLECULAR MEDICINE (2009)
FOXP3 Expression and Overall Survival in Breast Cancer
Andrea Merlo et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers
Anna Lissina et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2009)
WT1 (WILMS TUMOR 1) PEPTIDE IMMUNOTHERAPY FOR CHILDHOOD RHABDOMYOSARCOMA: A Case Report
Hideaki Ohta et al.
PEDIATRIC HEMATOLOGY AND ONCOLOGY (2009)
WT1 peptide vaccine for the treatment of cancer
Yoshihiro Oka et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
Dendritic cell-based cancer vaccination:: quo vadis?
M. Dauer et al.
EXPERT REVIEW OF VACCINES (2008)
Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes
Nathalie Demotte et al.
IMMUNITY (2008)
Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme
Shuichi Izumoto et al.
JOURNAL OF NEUROSURGERY (2008)
Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies
Katayoun Rezvani et al.
BLOOD (2008)
Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma
Akihiro Tsuboi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2007)
Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 μg/body) in a patient with chronic myelomonocytic leukemia
Manabu Kawakami et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2007)
WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma
Tatsuo Iiyama et al.
MICROBIOLOGY AND IMMUNOLOGY (2007)
Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers
Y. Oka et al.
CURRENT MEDICINAL CHEMISTRY (2006)
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells
J Dannull et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression
Y Oka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
N-acetylglucosaminyltransferase V (Mgat5)-Mediated N-glycosylation negatively regulates Th1 cytokine production by T cells
R Morgan et al.
JOURNAL OF IMMUNOLOGY (2004)
Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity
V Mailander et al.
LEUKEMIA (2004)
WT1 peptide-based immunotherapy for patients with lung cancer: Report of two cases
A Tsuboi et al.
MICROBIOLOGY AND IMMUNOLOGY (2004)
Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis
Y Oka et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2003)
Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus
V Karanikas et al.
JOURNAL OF IMMUNOLOGY (2003)
Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues
A Tsuboi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2002)
Share Paper
